Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CLOVER: Durvalumab + Chemoradiation in Advanced Solid Tumors
NCT03509012Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- May 2018
- Primary completion
- Dec 2020
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 5
01
Overview
Phase 1, open-label trial of durvalumab and tremelimumab in head and neck squamous cell carcinoma (HNSCC), non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) (8 arms), sponsored by AstraZeneca. Primary endpoints: Dose Limiting Toxicities at 28 days and Adverse Events at 90 days. Started May 2018; status: completed.
02
Drugs
durvalumabtremelimumab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)non-small cell lung cancer (NSCLC)small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT03509012.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03509012.